","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"about":[{"@type":"Corporation","tickerSymbol":"NYSE TEVA"}],"publisher":{"@type":"Organization","@id":"https://www.fool.com/","name":"The Motley Fool","url":"https://www.fool.com/","logo":{"@type":"ImageObject","url":"https://g.foolcdn.com/misc-assets/logo-tmf-primary-7-magenta-royalpurple.svg","width":"157","height":"43"},"brand":"The Motley Fool","contactPoint":{"@type":"ContactPoint","contactType":"Media Inquiries","email":"[email protected]"},"publishingPrinciples":"https://www.fool.com/about/","sameAs":["https://www.fool.com/about/","https://en.wikipedia.org/wiki/The_Motley_Fool","https://www.wikidata.org/wiki/Q7752442","https://www.linkedin.com/company/the-motley-fool","https://www.facebook.com/themotleyfool/","https://x.com/themotleyfool","https://www.instagram.com/themotleyfoolofficial/","https://www.youtube.com/channel/UCpRQuynBX9Qy9tPrcswpPag","https://www.pinterest.com/themotleyfool/","https://www.tiktok.com/@themotleyfoolofficial","https://www.google.com/search?kgmid=/m/0578mk"]},"description":"The market may not be enthusiastic about Teva's stock, but what can the company do to boost investor confidence?","image":{"@type":"ImageObject","height":"630","width":"1200"}}","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"inLanguage":"en-US"}

Can Teva Turn Things Around?

The market may not be enthusiastic about Teva's stock, but what can the company do to boost investor confidence?

By Max Macaluso and Dave Williamson – Sep 17, 2013 at 10:59PM EST

Shares of the largest generic drug company in the world, Teva Pharmaceuticals (TEVA 2.46%), are down more than 7.5% in the last 12 months. This drop largely has to do with fears that biosimilars of the multiple sclerosis drug Copaxone, which currently accounts for a fifth of Teva's top line, may enter the market in the next couple of years. But what growth opportunities does the company have in the future, and what moves can it make to boost investor confidence? Analysts David Williamson and Max Macaluso discuss this topic in this segment from the Motley Fool's health-care show Market Checkup.

Read Next

Mar 2, 2026 •By Thomas Niel

The Best Healthcare Stock to Invest $1,000 in Right Now

Feb 27, 2026 •By Reuben Gregg Brewer

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole

Dec 24, 2025 •By Sean Williams

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

Dec 17, 2025 •By Reuben Gregg Brewer

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today

Dec 14, 2025 •By Reuben Gregg Brewer

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?

Nov 30, 2025 •By Bram Berkowitz

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks

About the Author

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs. Follow @TMFMassimo

TMFMassimo

Stocks Mentioned

Teva Pharmaceutical Industries

NYSE: TEVA

$30.62

(-2.85%)-$0.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.